Aclaris Therapeutics Inc. (ACRS)
ACRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1557746/000110465926020540/0001104659-26-020540-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ACRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001557746 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.8M |
| Net income | -$64.9M |
| Operating income | -$76.4M |
| Net margin | -829.6% |
| Operating margin | -975.9% |
| Revenue growth | -58.2% |
| Cash | $20.0M |
| Total assets | $160.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 73.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $20.4M cash; operating cash flow -$18.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 158,612,149 (2026-10-30); 108,345,239 a year earlier; 70,836,194 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-10-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.5M | -$18.5M | -$24.1M | $20.4M | No debt tags | $6.4M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.6M | -$21.5M | -$19.8M | $19.2M | No debt tags | $8.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.0M | -$19.8M | -$18.1M | $28.7M | No debt tags | $8.4M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $1.3M | -$19.8M | -$13.1M | $20.0M | No debt tags | $7.8M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $3.3M | -$14.6M | -$10.9M | $25.3M | No debt tags | $15.7M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $1.8M | -$15.4M | -$10.0M | $25.4M | No debt tags | $16.8M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.5M | -$15.1M | -$13.1M | $30.4M | No debt tags | $17.8M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $9.2M | -$96.6M | -$8.9M | $24.6M | No debt tags | $18.7M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-27 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 874 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +13.0% |
| 3 months | -33.1% |
| Year to date | +30.2% |
| 1 year | +69.0% |
| From 52-week high | -40.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| ZVRA | Zevra Therapeutics Inc. | $9.25 | +1.87% | $550.4M |
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
| GERN | Geron Corporation | $0.9419 | -2.60% | $606.8M |
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier